Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry
Bayram Farisogullari,Saskia Lawson-Tovey,Kimme L Hyrich,Laure Gossec,Loreto Carmona,Anja Strangfeld,Elsa F Mateus,Martin Schäfer,Ana Rodrigues,Eric Hachulla,Jose A Gomez-Puerta,Marta Mosca,Patrick Durez,Ludovic Trefond,Tiphaine Goulenok,Martina Cornalba,Emoke Stenova,Inita Bulina,Eva Strakova,Julija Zepa,Nicolas Roux,Olivier Brocq,Eric Veillard,Bernd Raffeiner,Gerd R Burmester,Xavier Mariette,Pedro M Machado,EULAR COVAX Registry,Viviane Queyrel,Julien Henry,Raphaele Seror,Eric Toussirot,Azeddine Dellal,Vanda Mlynarikova,Romain Forestier,François Lamer,Hélène Maillard,Amélie Leurs,Thierry Zenone,Daniel Wendling,Amélie Florent,Theodoros Dimitroulas,Simona Rednic,Bernard Combe,Yves Piette,Jozef Odnoga,Giovanna Cuomo,Ioannis Raftakis,Jean-Camille Meric,Sylvain Lanot,Marion Mirabel,Mikhail Protopopov,Katalin Törõcsik,John Brockbank,Marion Jacob,Pascal Coquerelle,Christophe Richez,Elisabeth Gervais,Séverine Verlinden,Antoine Froissart,Fabienne Roux,Marion Couderc,Renaud Desbarbieux,Alojzija Hocevar,Pierre-Yves Jeandel,Sophie Rivière,Luciana Popa,Fabienne Coury,Jean-Jacques Dubost,Lionel Spielmann,Marie-Hélène Guyot,Nicolas Deseyne,Isabelle Amigues,Dagmar Mičeková,Loraine Gauzere,Gaëlle Viadere,Natalia de la Torre-Rubio,Victor Strotz
DOI: https://doi.org/10.1136/ard-2024-225869
2024-10-21
Abstract:Objectives: To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs). Methods: Data from the European Alliance of Associations for Rheumatology Coronavirus Vaccine physician-reported registry were used. Factors associated with flare in patients with I-RMDs were investigated using multivariable logistic regression adjusted for demographic and clinical factors. Results: The study included 7336 patients with I-RMD, with 272 of 7336 (3.7%) experiencing flares and 121 of 7336 (1.6%) experiencing flares requiring starting a new medication or increasing the dosage of an existing medication. Factors independently associated with increased odds of flare were: female sex (OR=1.40, 95% CI=1.05 to 1.87), active disease at the time of vaccination (low disease activity (LDA), OR=1.45, 95% CI=1.08 to 1.94; moderate/high disease activity (M/HDA), OR=1.37, 95% CI=0.97 to 1.95; vs remission), and cessation/reduction of antirheumatic medication before or after vaccination (OR=4.76, 95% CI=3.44 to 6.58); factors associated with decreased odds of flare were: higher age (OR=0.90, 95% CI=0.83 to 0.98), non-Pfizer/AstraZeneca/Moderna vaccines (OR=0.10, 95% CI=0.01 to 0.74; vs Pfizer), and exposure to methotrexate (OR=0.57, 95% CI=0.37 to 0.90), tumour necrosis factor inhibitors (OR=0.55, 95% CI=0.36 to 0.85) or rituximab (OR=0.27, 95% CI=0.11 to 0.66), versus no antirheumatic treatment. In a multivariable model using new medication or dosage increase due to flare as the dependent variable, only the following independent associations were observed: active disease (LDA, OR=1.47, 95% CI=0.94 to 2.29; M/HDA, OR=3.08, 95% CI=1.91 to 4.97; vs remission), cessation/reduction of antirheumatic medication before or after vaccination (OR=2.24, 95% CI=1.33 to 3.78), and exposure to methotrexate (OR=0.48, 95% CI=0.26 to 0.89) or rituximab (OR=0.10, 95% CI=0.01 to 0.77), versus no antirheumatic treatment. Conclusion: I-RMD flares following SARS-CoV-2 vaccination were uncommon. Factors associated with flares were identified, namely higher disease activity and cessation/reduction of antirheumatic medications before or after vaccination.